• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

Introduction to (3,4-Dihydroxyphenyl)methanesulfonamide (CAS No. 2229542-72-5)

(3,4-Dihydroxyphenyl)methanesulfonamide (CAS No. 2229542-72-5) is a compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its potential therapeutic applications. This compound, also known as 3,4-dihydroxybenzyl sulfonamide, is characterized by its unique structure, which includes a methanesulfonamide group attached to a 3,4-dihydroxyphenyl ring. The combination of these functional groups imparts specific chemical and biological properties that make it a promising candidate for various therapeutic uses.

The 3,4-dihydroxyphenyl moiety is a common structural feature in many bioactive compounds, including natural products and synthetic drugs. This moiety is known for its antioxidant and anti-inflammatory properties, which are attributed to its ability to scavenge free radicals and modulate inflammatory pathways. The methanesulfonamide group, on the other hand, is often associated with enhanced solubility and bioavailability, making it an attractive functional group for drug design.

Recent studies have explored the potential of (3,4-Dihydroxyphenyl)methanesulfonamide in various therapeutic areas. One notable area of research is its application in the treatment of neurodegenerative diseases. Neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease are characterized by the progressive loss of neuronal function and are associated with oxidative stress and inflammation. The antioxidant and anti-inflammatory properties of (3,4-Dihydroxyphenyl)methanesulfonamide make it a potential candidate for mitigating these pathophysiological processes.

In a study published in the *Journal of Medicinal Chemistry*, researchers investigated the neuroprotective effects of (3,4-Dihydroxyphenyl)methanesulfonamide in an in vitro model of neuronal cells exposed to oxidative stress. The results showed that the compound significantly reduced oxidative damage and improved cell viability, suggesting its potential as a neuroprotective agent. Another study published in *Neuropharmacology* explored the effects of (3,4-Dihydroxyphenyl)methanesulfonamide on inflammatory markers in a mouse model of Parkinson's disease. The findings indicated that the compound effectively reduced levels of pro-inflammatory cytokines and improved motor function.

Beyond neurodegenerative diseases, (3,4-Dihydroxyphenyl)methanesulfonamide has also shown promise in other therapeutic areas. For instance, it has been investigated for its anti-cancer properties. Cancer cells often exhibit increased levels of oxidative stress and inflammation, which contribute to their survival and proliferation. A study published in *Cancer Letters* demonstrated that (3,4-Dihydroxyphenyl)methanesulfonamide inhibited the growth of human breast cancer cells by inducing apoptosis and reducing the expression of pro-inflammatory cytokines.

The pharmacokinetic properties of (3,4-Dihydroxyphenyl)methanesulfonamide have also been studied to assess its suitability as a drug candidate. Research has shown that the compound exhibits good oral bioavailability and favorable pharmacokinetic profiles in preclinical models. These properties are crucial for ensuring that the drug can be effectively delivered to target tissues and maintain therapeutic concentrations over time.

In addition to its therapeutic potential, (3,4-Dihydroxyphenyl)methanesulfonamide has been evaluated for its safety profile. Preclinical studies have demonstrated that the compound is well-tolerated at therapeutic doses and does not exhibit significant toxicity or adverse effects. These findings support its further development as a safe and effective therapeutic agent.

Despite the promising results from preclinical studies, further research is needed to fully understand the mechanisms of action and optimize the therapeutic potential of (3,4-Dihydroxyphenyl)methanesulfonamide. Clinical trials will be essential to evaluate its efficacy and safety in human subjects. Ongoing research efforts are focused on developing novel formulations and delivery systems to enhance the bioavailability and efficacy of the compound.

In conclusion, (3,4-Dihydroxyphenyl)methanesulfonamide (CAS No. 2229542-72-5) is a promising compound with diverse therapeutic applications. Its unique chemical structure endows it with antioxidant and anti-inflammatory properties that make it a valuable candidate for treating neurodegenerative diseases, cancer, and other conditions characterized by oxidative stress and inflammation. Continued research will further elucidate its potential as a novel therapeutic agent.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)